Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

#827

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Aim(s): To analyse the expression of CK19 as a possible criterion for a malignant potential of pNET-G2.

Materials and methods: We identified the labeling index (LI) Ki-67 (clone MIB-1) and the expression of cytokeratin 19 (CK19) in 112 pNET. In accordance with the LI-Ki-67 (0-5%, 5, 1-10% and more than 10%), we divided pNET tumors into three groups: pNET-I, II, III (57, 23, and 32 cases).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,